锐客网

  1. 首页 > 生活杂烩 > 健康 > >

乳腺癌|盘点 2020｜马飞教授：乳腺癌治疗新进展( 八 )


[9]GAO H F, WU Z, LIN Y, et al. Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(15_suppl):585-585.
[10]RAMSHORST M S V, VOORT A V D, WERKHOVEN E V, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(15_suppl):501-501.
[11]GLUZ O, NITZ U, CHRISTGEN M, et al. De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study[J]. J Clin Oncol, 2020, 38(15_suppl):515-515.
[12]HARBECK N, IM S A, BARRIOS C H, et al. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC)[J]. J Clin Oncol, 2020, 38(15_suppl):500-500.
[13]XU B, YAN M, MA F, et al. Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(15_suppl):1003-1003.
[14]YAMAMOTO Y, IWATA H, NARUTO T, et al. PD3-11 A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study[OL]. (2020-12-09)[2020-12-15]. https://www.abstractsonline.com/pp8/#!/9223/presentation/802.
[15]LIN N U, MURTHY R K, ANDERS C K, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)[J]. J Clin Oncol, 2020, 38(15_suppl):1005-1005.
[16]MURTHY RK, LOI S, OKINES A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer[J]. N Engl J Med, 2020, 382(7):597-609.
[17]MODI S, SAURA C, YAMASHITA T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer[J]. N Engl J Med, 2020, 382(7):610-621.
[18]MODI S, ANDRE F, KROP I E, et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis[J]. J Clin Oncol, 2020, 38(15_suppl):1036-1036.
[19]MODI S, SAURA C, YAMASHITA T, et al. PD3-06 Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer[OL]. (2020-12-09)[2020-12-15]. https://www.abstractsonline.com/pp8/#!/9223/presentation/797.
[20]TUNG N M, ROBSON M E, VENTZ S, et al. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)[J]. J Clin Oncol, 2020, 38(15_suppl):1002-1002.
[21]SHARMA P, RODLER E, BARLOW W E, et al. Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416)[J]. J Clin Oncol, 2020, 38(15_suppl):1001-1001.
[22]BARDIA A, MAYER I A, VAHDAT L T, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer[J]. N Engl J Med, 2019, 380(8):741-751.
[23]BARDIA A, TOLANEY S M, LOIRAT D, et al. LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)[J]. Ann Oncol, 2020, 31:S1149-S1150.
[24]LV M, MAO Y, SONG Y, et al. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients[J]. Clin Breast Cancer, 2020, 20(5):e589-e599.

推荐阅读


上一篇：减肥|减肥期间，养成这几个好习惯，坚持3个月，让体重不知不觉下降

下一篇：医院|【医疗】中国太平首家康复医院今日在沪投入试运行